Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Dec;93(12):1456-63.
doi: 10.1002/bjs.5624.

Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer

A D Thornton  1 , P Ravn, M Winslet, K Chester
Affiliations
Review

Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer

A D Thornton et al. Br J Surg. 2006 Dec.

Abstract

Background: Bevacizumab is an angiogenesis inhibitor and a new therapy for the treatment of colorectal cancer. It is a humanized monoclonal antibody that targets vascular endothelial growth factor.

Methods: This review is based on a literature search of Medline, Pubmed, ISI web of knowledge and other published work for original articles, reviews and abstracts relevant to the surgical management of colorectal cancer with bevacizumab.

Results and conclusion: Combined with current chemotherapy regimens, bevacizumab offers a significant survival advantage, making it likely to see widespread use. Despite being generally well tolerated, serious toxicities, including wound complications and gastrointestinal perforation, have been reported that affect surgical management. Consideration should be given to the timing of surgical and adjuvant intervention when using this drug.

PubMed Disclaimer

MeSH terms